INmune Bio Stock Options Expiring on 19th of September
| INMB Stock | USD 2.36 0.06 2.48% |
INmune Bio's latest option contracts expiring on September 19th 2025 are carrying combined implied volatility of 2.87 with a put-to-call open interest ratio of 0.6 over 24 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on September 19th 2025. The total put volume is at 843, with calls trading at the volume of 77.0. This yields a 10.95 put-to-call volume ratio.
Open Interest Against September 19th 2025 Option Contracts
2025-09-19
The chart above shows INmune Bio's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. INmune Bio's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for INmune Bio's option, there is no secondary market available for investors to trade.
INmune Bio Maximum Pain Price Across 2025-09-19 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as INmune Bio close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, INmune Bio's option sellers may reap the most after selling more options than buying, causing them to expire worthless.
INmune Bio's stock options are financial instruments that give investors the right to buy or sell shares of INmune Bio common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell INmune stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If INmune Bio's stock price goes up or down, the stock options follow.
At present, INmune Bio's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 41.8 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 13.9 M. INmune Bio In The Money Call Balance
When INmune Bio's strike price is surpassing the current stock price, the option contract against INmune Bio stock is said to be in the money. When it comes to buying INmune Bio's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on INmune Bio are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
INmune Current Options Market Mood
INmune Bio's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps INmune Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most INmune Bio's options investors are not very successful. INmune Bio's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current INmune contract
Base on the Rule 16, the options market is currently suggesting that INmune Bio will have an average daily up or down price movement of about 0.18% per day over the life of the 2025-09-19 option contract. With INmune Bio trading at USD 2.36, that is roughly USD 0.004233. If you think that the market is fully incorporating INmune Bio's daily price movement you should consider buying INmune Bio options at the current volatility level of 2.87%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
INmune Bio Option Chain
When INmune Bio's strike price is surpassing the current stock price, the option contract against INmune Bio stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
INmune Bio's option chain is a display of a range of information that helps investors for ways to trade options on INmune. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for INmune. It also shows strike prices and maturity days for a INmune Bio against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | INMB250919C00022500 | 0 | 22.5 | 0.0 - 0.75 | 0.75 | |
Call | INMB250919C00020000 | 6638 | 20.0 | 0.0 - 0.05 | 0.03 | Out |
Call | INMB250919C00017500 | 592 | 17.5 | 0.0 - 0.05 | 0.05 | Out |
Call | INMB250919C00015000 | 1986 | 15.0 | 0.0 - 0.75 | 0.02 | Out |
Call | INMB250919C00012500 | 1982 | 12.5 | 0.0 - 0.15 | 0.06 | Out |
Call | INMB250919C00010000 | 5549 | 10.0 | 0.0 - 0.2 | 0.1 | Out |
Call | INMB250919C00007500 | 990 | 7.5 | 0.0 - 0.1 | 0.05 | Out |
Call | INMB250919C00006000 | 0 | 6.0 | 0.0 - 4.8 | 4.8 | |
Call | INMB250919C00005000 | 1069 | 5.0 | 0.05 - 0.15 | 0.15 | Out |
Call | INMB250919C00004000 | 115 | 4.0 | 0.05 - 0.15 | 0.15 | Out |
Call | INMB250919C00002500 | 1044 | 2.5 | 0.4 - 0.5 | 0.45 | Out |
Call | INMB250919C00001000 | 25 | 1.0 | 1.2 - 1.55 | 1.4 | In |
Put | INMB250919P00022500 | 0 | 22.5 | 19.5 - 20.8 | 19.5 | In |
Put | INMB250919P00020000 | 422 | 20.0 | 17.2 - 18.8 | 17.97 | In |
Put | INMB250919P00017500 | 90 | 17.5 | 14.1 - 16.3 | 15.5 | In |
Put | INMB250919P00015000 | 52 | 15.0 | 11.6 - 13.1 | 12.8 | In |
Put | INMB250919P00012500 | 327 | 12.5 | 9.7 - 10.5 | 10.55 | In |
Put | INMB250919P00010000 | 980 | 10.0 | 6.4 - 7.9 | 7.8 | In |
Put | INMB250919P00007500 | 2932 | 7.5 | 5.0 - 5.4 | 5.15 | In |
Put | INMB250919P00006000 | 160 | 6.0 | 2.8 - 4.0 | 3.95 | In |
Put | INMB250919P00005000 | 1035 | 5.0 | 2.55 - 2.9 | 2.79 | In |
Put | INMB250919P00004000 | 3241 | 4.0 | 1.5 - 2.8 | 1.9 | In |
Put | INMB250919P00002500 | 2425 | 2.5 | 0.5 - 0.6 | 0.57 | In |
Put | INMB250919P00001000 | 249 | 1.0 | 0.05 - 0.1 | 0.05 | Out |
INmune Bio Market Cap Over Time
Market Cap |
| Timeline |
INmune Total Stockholder Equity
Total Stockholder Equity |
|
INmune Bio Corporate Management
| Christopher Barnum | Head Neuroscience | Profile | |
| BSc FRCPath | Chief Officer | Profile | |
| Mark Lowdell | Chief Officer | Profile | |
| Raymond MD | President, CoFounder | Profile | |
| Joshua Esq | General Counsel | Profile | |
| David MBA | Treasurer CFO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.93) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.